Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis

International Journal of Dermatology

Volumn 55, Issue 11, 2016, Pages 1259-1267

  Jafarinejad Farsangi, Saeideh ^a   Farazmand, Ali ^a   Gharibdoost, Farhad ^b   Karimizadeh, Elham ^a   Noorbakhsh, Farshid ^b   Faridani, Habibeh ^b   Mahmoudi, Mahdi ^b   Jamshidi, Ahmad Reza ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA 21; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BAX GENE; BCL 2 GENE; CELL FATE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; STAINING; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

EID: 84989855614     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.13308     Document Type: Article

References (57)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557–567.
2. Cai K, Lv Z, Chen K, et al. Aqueous synthesis of porous platinum nanotubes at room temperature and their intrinsic peroxidase-like activity. Chem Commun (Camb) 2013; 49: 6024–6026.
3. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010; 37: 11–25.
4. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005; 258: 479–517.
5. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–257.
6. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501–507.
7. Kissin E, Korn JH. Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis. Curr Rheumatol Rep 2002; 4: 129–135.
8. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001; 40: 275–284.
9. Poon IK, Lucas CD, Rossi AG, et al. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 2014; 14: 166–180.
10. Dewson GKRM. Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskelet 2010; 2: 9–22.
11. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003; 15: 691–699.
12. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157–164.
13. Harnois DM, Que FG, Celli A, et al. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997; 26: 884–890.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619.
15. Annis MG, Soucie EL, Dlugosz PJ, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24: 2096–2103.
16. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166–1173.
17. Garchow BG, Bartulos Encinas O, Leung YT, et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 2011; 3: 605–615.
18. Salaun B, Yamamoto T, Badran B, et al. Differentiation associated regulation of microRNA expression in vivo in human CD8 + T cell subsets. J Transl Med 2011; 9: 44.
19. Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70: 1496–1506.
20. Xu WD, Pan HF, Li JH, et al. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets 2013; 17: 659–665.
21. Wang T, Feng Y, Sun H, et al. miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am J Pathol 2012; 181: 1911–1120.
22. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589–1597.
23. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22: 1668–1681.
24. Zhu H, Li Y, Qu S, et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012; 32: 514–522.
25. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 2014; 5: 123.
26. Eckes B, Moinzadeh P, Sengle G, et al. Molecular and cellular basis of scleroderma. J Mol Med (Berl) 2014; 92: 913–924.
27. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230–2239.
28. Santiago B, Galindo M, Rivero M, et al. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001; 44: 1667–1676.
29. Jafarinejad-Farsangi S, Farazmand A, Mahmoudi M, et al. MicroRNA-29a induces apoptosis via increasing the Bax: Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 2015; 48: 369–378.
30. Karimizadeh E, Gharibdoost F, Motamed N, et al. c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts. Mol Cell Biochem 2015; 405: 169–176.
31. Zhu H, Luo H, Li Y, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression. J Clin Immunol 2013; 33: 1100–1109.
32. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029–6033.
33. Ruan Q, Wang P, Wang T, et al. MicroRNA-21 regulates T cell apoptosis by directly targeting the tumor suppressor gene Tipe2. Cell Death Dis 2014; 5: e1095.
34. Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009; 106: 12085–12090.
35. Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer 2011; 30: 371–380.
36. Dong J, Zhao YP, Zhou L, et al. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 2011; 42: 8–14.
37. Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 2014; 7: 565–574.
38. Hassan M, Watari H, Abu Almaaty A, et al. Apoptosis and molecular targeting therapy in Cancer. Biomed Res Int 2014; 2014: 150845.
39. Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123: 1096–1108.
40. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920–3927.
41. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126–1132.
42. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003; 30: 143–149.
43. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812–1823.
44. Wei J, Kitada S, Rega MF, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2009; 8: 904–913.
45. Leone E, Morelli E, Di Martino MT, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013; 19: 2096–2106.
46. Sicard F, Gayral M, Lulka H, et al. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 2013; 21: 986–994.
47. Thum T, Chau N, Bhat B, et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 2011; 121: 461–462; author reply 462–463.
48. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics 2014; 2014: 970607.
49. Ma Y, Yang HZ, Dong BJ, et al. Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia. Oncotarget 2014; 5: 9169–9182.
50. Gao X, Qiao Y, Han D, et al. Enemy or partner: relationship between intronic micrornas and their host genes. IUBMB Life 2012; 64: 835–840.
51. Ribas J, Ni X, Castanares M, et al. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res 2012; 40: 6821–6833.
52. Vaccaro MI, Ropolo A, Grasso D, et al. A novel mammalian trans-membrane protein reveals an alternative initiation pathway for autophagy. Autophagy 2008; 4: 388–390.
53. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741–752.
54. Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47–51.
55. Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor-β and Smad without evidence of renin–angiotensin system involvement. J Am Acad Dermatol 2008; 58: 1025–1030.
56. Bettinger DA, Yager DR, Diegelmann RF, et al. The effect of TGF-β on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 1996; 98: 827–833.
57. Smith P, Mosiello G, Deluca L, et al. TGF-β2 activates proliferative scar fibroblasts. J Surg Res 1999; 82: 319–323.